🇺🇸 Artificial intelligence is reshaping biotech, drug discovery and medicine. But how much of the AI revolution is real, how much is hype, and what could it mean for the future of American medicine?

In Part 6 of our How America Makes Medicine series, host John Stanford sits down with physician-scientist and venture capitalist Patrick Malone to explore how AI and machine learning could transform drug development, biotech investing and the way new medicines reach patients.

Could AI agents and computational drug discovery allow a handful of people, or even one founder, to build a billion-dollar biotech company? Can better access to clinical trial and regulatory data accelerate innovation? And if AI makes drug discovery faster and cheaper, can it overcome the industry's biggest bottleneck: clinical trials?

John and Patrick also examine the future of U.S. biotechnology, FDA modernization, venture capital, China's growing biotech capabilities and what America must do to remain a global leader in life sciences.

Plus, John breaks down the latest biotech headlines and traces the evolution of AI in medicine, from early computer models and the Human Genome Project to AlphaFold and today's AI-driven drug discovery platforms.

What happens next could reshape how America makes medicine. It’s an important conversation about the future of biotech you can’t afford to miss.

We explore
🔹 What's real, and overhyped, about AI drug discovery
🔹 The rise of smaller, AI-powered biotech companies
🔹 Why clinical trials remain a critical bottleneck
🔹 The widening "Valley of Death" for biotech innovation
🔹 Clinical and regulatory data's role in the AI revolution
🔹 FDA modernization and Operation Trial Blazer
🔹 Venture capital and the future of drug development
🔹 U.S. biotechnology leadership and competition with China
🔹 What the next generation of American biotech could look like  

This episode is part of How America Makes Medicine, a seven-part series exploring the people, science, institutions, and business decisions behind 250 years of American pharmaceutical innovation.

From research universities and biotechnology startups to pharmaceutical manufacturers, investors, regulators and patients, the series examines how America's medicine ecosystem was built and what it will take to keep innovating.

Join the Conversation ⬇️
How much do you think AI will change the way new medicines are discovered and developed over the next decade?
Could a one-person or small-team biotech really become a billion-dollar company, or is the industry too complex for that model?
What should America prioritize most to remain a global leader in biotechnology: AI and data, faster drug development, more investment, or stronger domestic capabilities?
Drop your thoughts in the comments below👇

👍 Subscribe to the Making Medicine Podcast so you don't miss the next chapter of How America Makes Medicine, our seven-part series celebrating 250 years of American pharmaceutical innovation.

If you're new to the Making Medicine Podcast, we're happy you're here! Follow us for more:
https://x.com/MakingMedPod
https://www.instagram.com/makingmedicinepod/
https://www.linkedin.com/showcase/making-medicine-podcast/about/?viewAsMember=true  

Timestamps
00:00  Could One Person Build a Billion-Dollar Biotech?
00:17  How America Will Make Medicine
01:36  This Week in Biotech: Headlines
03:34  The History of AI in Drug Discovery
10:08  Meet Patrick Malone: From Medicine to Venture Capital
15:07  AI Drug Discovery: What's Real and What's Hype?
17:32  The Billion-Dollar Biotech of the Future
21:51  What's Changing in Biotech Venture Capital?
23:49  Is Biotech's Valley of Death Getting Wider?
25:36  Does America Have the Data AI Needs?
29:28  Why Biotech Needs a Stronger Voice in Washington
32:30  Faster Drug Development and Operation Trial Blazer
35:04  U.S. Biotech, China and the Future of Competition
45:58  Closing

DISCLAIMER: We're reporting on the headlines, not making medical recommendations. For personal health questions, always consult a doctor.

#ArtificialIntelligence #Biotechnology #DrugDiscovery #FutureOfMedicine #MakingMedicine